Brigit Biofarmaka Teknologi Tbk. vs Reksa Dana Indeks SAM ETF SRI-KEHATI — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp254 (market cap 172.82B, 592.2K 24h volume), while Reksa Dana Indeks SAM ETF SRI-KEHATI trades at Rp666 (market cap 11.92B). The key difference: Brigit Biofarmaka Teknologi Tbk. is far larger — about 14.5× Reksa Dana Indeks SAM ETF SRI-KEHATI's market cap. Which is the better fit depends on your goals.
| OBAT | XSSK | |
|---|---|---|
Market Cap | 172.82B | 11.92B |
Volume | 592.2K | — |
Lot | 5.92K | — |
Turnover | 147.05M | — |
Average Price | 248.31 | — |
Value | 147.05M | — |
Indicative Equilibrium Price | 254 | — |
Indicative Equilibrium Volume | 10 | — |
Trailing returns across standard periods
Latest headlines on both assets
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →